{"product_id":"jointown-business-model-canvas","title":"Jointown Pharmaceutical Group Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJointown Pharma: Business Model Canvas \u0026amp; Strategic Insight Toolkit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the business logic behind Jointown Pharmaceutical Group's growth with a focused Business Model Canvas that highlights its value proposition, key partners, customer segments, and revenue structure across pharmaceuticals, medical devices, and traditional Chinese medicines. Built for investors, analysts, and business planners, this downloadable Word \u0026amp; Excel package offers a clear, company-specific view of how Jointown serves hospitals, pharmacies, and healthcare institutions while supporting ongoing product development and manufacturing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal and Domestic Pharmaceutical Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJointown maintains alliances with over 4,500 global and domestic manufacturers, securing a diversified drug supply and exclusive distribution for high-demand innovative and generic drugs that accounted for ~28% of 2024 revenue (RMB 14.2bn). By 2025 these partners share real-time sales and inventory data via integrated platforms, cutting stockouts 35% and lowering working capital tied to inventory by an estimated RMB 1.1bn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Agencies and Regulatory Bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJointown collaborates with provincial and national health authorities to meet updated GSP (Good Supply Practice) standards, supporting over 12,000 public hospitals and community clinics and maintaining \u0026gt;20% share in centralized drug procurement by value as of 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and Digital Infrastructure Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy end-2025 Jointown Pharmaceutical Group partners with global cloud and AI firms (including Alibaba Cloud and Huawei Cloud partners) to run IoT-enabled cold-chain tracking and AI-driven automated warehousing, cutting order-to-delivery time by ~18% and reducing temperature excursion losses by ~30% across its 2,800+ distribution centers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Institutions and Fintech Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJointown partners with banks and fintechs to offer supply-chain financing to ~200,000 small pharmacies\/clinics in its network, improving downstream cash flow and reducing days payable outstanding by an estimated 12-18 days as of 2025.\u003c\/p\u003e\n\u003cp\u003eIntegrated payment systems rolled out by 2025 cut B2B transaction times by ~40%, stabilizing the distribution ecosystem and lowering short-term liquidity risks for suppliers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~200,000 downstream partners\u003c\/li\u003e\n\u003cli\u003e12-18 days reduction in DPO\u003c\/li\u003e\n\u003cli\u003e40% faster B2B transactions (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird Party E-commerce and Delivery Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrategic ties with major Chinese consumer platforms (Taobao, JD Health, Pinduoduo) let Jointown scale O2O pharmaceutical retail, contributing to online sales growth-Jointown reported 2024 online revenue of RMB 8.2 billion, up 18% year-on-year.\u003c\/p\u003e\n\u003cp\u003eThese partnerships enable rapid home delivery of OTC meds and health products by combining Jointown's inventory (warehouses in 30+ cities) with courier last-mile expertise, often achieving same-day delivery in tier-1\/2 cities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 online revenue RMB 8.2bn\u003c\/li\u003e\n\u003cli\u003e18% y\/y online growth (2024)\u003c\/li\u003e\n\u003cli\u003eWarehouses in 30+ cities\u003c\/li\u003e\n\u003cli\u003eSame-day delivery in tier-1\/2 cities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJointown drives 28% revenue via 4,500+ partners, cutting stockouts 35% and boosting online growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJointown's 4,500+ manufacturer partners supplied ~28% of 2024 revenue (RMB 14.2bn); integrated data-sharing cut stockouts 35% and freed ~RMB 1.1bn in inventory working capital by 2025. Partnerships with banks, cloud\/AI firms, and platforms (Alibaba Cloud, Huawei partners, Taobao, JD Health) enabled supply-chain finance for ~200,000 outlets, 40% faster B2B payments, 18% online growth (RMB 8.2bn, 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturer partners\u003c\/td\u003e\n\u003ctd\u003e4,500+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 rev from partners\u003c\/td\u003e\n\u003ctd\u003eRMB 14.2bn (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDownstream partners\u003c\/td\u003e\n\u003ctd\u003e~200,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline rev 2024\u003c\/td\u003e\n\u003ctd\u003eRMB 8.2bn (18% y\/y)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockout reduction\u003c\/td\u003e\n\u003ctd\u003e35% (by 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eB2B payment speed\u003c\/td\u003e\n\u003ctd\u003e+40% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Jointown Pharmaceutical Group detailing customer segments, channels, value propositions, key activities, resources, partnerships, revenue streams, cost structure, and risks; reflects real-world distribution, healthcare services, and B2B\/B2C operations for investor presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Jointown Pharmaceutical Group's business model with editable cells-quickly pinpoint distribution, manufacturing, and healthcare service strengths to streamline strategy and relieve analysis bottlenecks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmart Logistics and Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJointown coordinates receiving, storing, and shipping over 2.2 million medical units daily, using automated sorting and cold-chain tech to cut spoilage below 0.6% and achieve 98.4% on-time delivery; warehousing and logistics made up about 54% of 2024 logistics segment revenue (roughly $2.1 billion). By 2025 the group is deploying predictive analytics across 120 regional hubs to reduce stockouts by an expected 35% and lower expedited shipping costs by ~18%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Wholesale and Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJointown operates China's largest pharmaceutical wholesale network, buying \u0026gt;¥180 billion (2024 revenue basis) in goods annually, managing 3,000+ SKUs per region and 2,500+ distribution centers to link 700,000+ hospitals, clinics and pharmacies.\u003c\/p\u003e\n\u003cp\u003eIts activities cover bulk procurement, centralized inventory control and automated order fulfillment, with route optimization cutting transport costs ~6% and improving rural delivery windows to 48-72 hours.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Platform Operation and Maintenance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperating Jointown Pharmaceutical Group's B2B platform powers catalogs, ordering, and real-time shipment tracking for ~80,000 pharmacy and clinic customers, handling about ¥60 billion (RMB) in annual online transactions in 2024; it is the primary procurement touchpoint and drives ~35% of incremental revenue growth. Continuous updates preserve PCI-level security, improve UX, and enable API links with major customer ERP\/CRM systems, reducing order errors by ~22%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJointown operates and franchises over 7,200 retail pharmacies in China (2024), handling store design, local SKU curation, POS systems, and professional pharmacy consultations to drive avg. same-store sales growth of ~6% in 2024.\u003c\/p\u003e\n\u003cp\u003eThis unit tracks consumer trends, OTC demand, and regional health needs weekly, supporting inventory turns of ~8x\/yr and contributing roughly 18% of group revenue in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e7,200+ stores (2024)\u003c\/li\u003e\n\u003cli\u003eAvg. same-store sales +6% (2024)\u003c\/li\u003e\n\u003cli\u003eInventory turns ~8x\/year\u003c\/li\u003e\n\u003cli\u003e~18% of group revenue (2024)\u003c\/li\u003e\n\u003cli\u003eWeekly consumer trend monitoring\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development in Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJointown Pharmaceutical Group runs R\u0026amp;D and manufacturing for targeted pharma and traditional Chinese medicines, conducting clinical trials and patent filings while operating GMP-grade plants; by Dec 2025 it shifted toward high-margin proprietary drugs, increasing in-house product revenue to about 14% of total sales (2025 guidance).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical trials: \u0026gt;30 ongoing (2025)\u003c\/li\u003e\n\u003cli\u003ePatents: 120+ filings cumulative (2025)\u003c\/li\u003e\n\u003cli\u003eManufacturing: multiple GMP lines, capacity +18% y\/y (2024-25)\u003c\/li\u003e\n\u003cli\u003eProprietary product share: ~14% revenue (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJointown: 2.2M units\/day, ¥180B\/yr, 7,200+ stores-logistics-led omni‑channel powerhouse\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJointown runs nationwide procurement, warehousing, omni-channel distribution and retail ops-processing \u0026gt;2.2M units\/day, ¥180B goods\/year, 2,500+ DCs, 7,200+ stores; logistics = ~54% logistics revenue (~$2.1B, 2024), online ¥60B sales (2024), proprietary drugs ~14% revenue (2025 guidance).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnits\/day\u003c\/td\u003e\n\u003ctd\u003e2.2M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual goods\u003c\/td\u003e\n\u003ctd\u003e¥180B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution centers\u003c\/td\u003e\n\u003ctd\u003e2,500+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStores (2024)\u003c\/td\u003e\n\u003ctd\u003e7,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline sales (2024)\u003c\/td\u003e\n\u003ctd\u003e¥60B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProprietary share (2025)\u003c\/td\u003e\n\u003ctd\u003e~14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the actual Jointown Pharmaceutical Group Business Model Canvas, not a mockup-it's a direct snapshot of the file you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll get full access to this same professional, ready-to-use document, formatted and editable exactly as shown, with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive National Warehousing Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJointown operates over 30 large-scale distribution centers and 120+ regional warehouses, plus 45 specialized cold-chain facilities as of 2025, covering all 31 Chinese provinces and 95% of tier-one and county-level markets; this network handled RMB 120 billion in distribution volume in 2024, creating a high fixed-cost barrier to entry and underpinning same-day\/next-day service reliability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Digital and AI Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJointown's proprietary logistics management software and analytics engines are a core intellectual resource, processing over 1.2 billion annual transactions and managing a 2024 inventory turnover of 14.5x to optimize procurement, warehousing, and last-mile delivery.\u003c\/p\u003e\n\u003cp\u003eBy 2025, integrated AI demand-forecasting models cut stockouts 27% and reduced working capital by an estimated CNY 3.4 billion, becoming the primary driver of measurable operational efficiency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Reputation and Industry Trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDecades of reliable service have made Jointown Pharmaceutical Group (listed 2016, market cap ~CNY 80bn as of Dec 2025) a brand tied to quality and regulatory compliance in China; that reputation helped win 2024 government procurement contracts worth CNY 12.6bn and secure distribution deals with global manufacturers representing \u0026gt;15% of its FY2024 product mix. Trust from hospitals and pharmacies drives repeat orders, supporting stable revenue-FY2024 gross margin 17.4% and ~80% client retention in core segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkilled Workforce and Specialized Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJointown employs ~45,000 staff (2024 annual report) across logistics, pharmacy, software engineering and sales; this mix drives pharma care quality and platform innovation, supporting 2024 revenue of RMB 93.1 billion (~US$13.6B).\u003c\/p\u003e\n\u003cp\u003eContinuous training covers new Chinese medical regs and cold-chain tech; internal training hours averaged 28 per employee in 2024, reducing supply errors by 12% year-over-year.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiverse roles: logistics, pharmacists, engineers, sales\u003c\/li\u003e\n\u003cli\u003eScale: ~45,000 employees (2024)\u003c\/li\u003e\n\u003cli\u003eRevenue: RMB 93.1B (2024)\u003c\/li\u003e\n\u003cli\u003eTraining: 28 hrs\/employee (2024)\u003c\/li\u003e\n\u003cli\u003eSupply errors down 12% YoY\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Liquidity and Capital Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJointown's strong liquidity-cash and equivalents of RMB 10.2 billion and net debt\/EBITDA around 0.8x at FY2024-lets it fund warehouse tech, keep large medicine inventories, and absorb low-margin volatility.\u003c\/p\u003e\n\u003cp\u003eReady access to equity and bank credit supported RMB 3.6 billion M\u0026amp;A deals in 2023-24, enabling faster regional rollouts and scale economies critical for high-volume distribution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash \u0026amp; equivalents: RMB 10.2bn (FY2024)\u003c\/li\u003e\n\u003cli\u003eNet debt\/EBITDA: ~0.8x (FY2024)\u003c\/li\u003e\n\u003cli\u003eM\u0026amp;A spend 2023-24: RMB 3.6bn\u003c\/li\u003e\n\u003cli\u003eSupports inventories, infra, and low-margin scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated cold-chain logistics leader: 30+ DCs, 1.2B txns, RMB10.2bn cash, 0.8x net debt\/EBITDA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore assets: 30+ distribution centers, 120+ regional warehouses, 45 cold-chain sites (2025); proprietary logistics\/AI platform (1.2B txns, 14.5x inventory turnover, stockouts -27%); brand\/regulatory trust (CNY 12.6bn govt contracts 2024); ~45,000 staff; RMB 10.2bn cash; net debt\/EBITDA ~0.8x (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDist centers\u003c\/td\u003e\n\u003ctd\u003e30+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional wh\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain\u003c\/td\u003e\n\u003ctd\u003e45\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransactions (ann.)\u003c\/td\u003e\n\u003ctd\u003e1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory turnover\u003c\/td\u003e\n\u003ctd\u003e14.5x (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003eRMB 10.2bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive One Stop Procurement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJointown Pharmaceutical Group supplies over 300,000 SKUs-Western medicines, traditional Chinese medicines, and medical devices-allowing hospitals and pharmacies to cut vendor count by up to 60% and reduce procurement lead time by 25% (Jointown 2024 distribution metrics). Customers gain a single, audited source for inventory, reducing working capital tied to suppliers and lowering stockout risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid and Reliable Delivery Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJointown's sophisticated logistics network guarantees timely delivery of life‑saving drugs and hospital supplies; by 2025 the firm reduced average order-to-door time to 18 hours nationwide via automated sorting and optimized transport routes, supporting 98.6% on‑time delivery and cutting hospital on‑site inventory by an estimated 22% versus 2020.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Transparency and Efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThrough Jointown's B2B platforms customers get real-time visibility into stock, pricing, and shipment status-Jointown reported 2024 platform orders grew 28% year-over-year to ¥45.8 billion (≈$6.6B), cutting order-to-fulfill time by 22%.\u003c\/p\u003e\n\u003cp\u003eThat transparency improves partners' cash forecasting and inventory turns (Jointown cites a 15% rise in turns for digital adopters) and online ordering trims admin time and procurement errors, lowering supply-chain costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Standards of Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJointown enforces strict GSP (Good Supply Practice) compliance and advanced cold-chain monitoring across 2,300+ logistics sites, cutting product spoilage and temperature breaches to under 0.5% in 2024 and lowering counterfeit entry risk through real-time traceability.\u003c\/p\u003e\n\u003cp\u003eThis quality focus preserves drug efficacy, supports regulatory compliance, and protects revenues-Jointown reported CNY 108.5 billion revenue from distributon in 2024 tied to strengthened QA controls.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGSP compliance across 2,300+ sites\u003c\/li\u003e\n\u003cli\u003eCold-chain breaches \u0026lt;0.5% (2024)\u003c\/li\u003e\n\u003cli\u003eReal-time traceability to block counterfeits\u003c\/li\u003e\n\u003cli\u003eCNY 108.5B distribution revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost Effective Supply Chain Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJointown leverages group-wide procurement (2024 revenue RMB 315.6 billion) to secure 5-12% lower drug and PPE prices versus regional wholesalers, passing savings to hospitals and pharmacies.\u003c\/p\u003e\n\u003cp\u003eThe firm bundles inventory management and logistics consulting-reducing clients' carrying costs by ~10% and stockouts by 30%-so providers stretch budgets while keeping service quality high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRMB 315.6B revenue (2024)\u003c\/li\u003e\n\u003cli\u003e5-12% price advantage\u003c\/li\u003e\n\u003cli\u003e~10% lower carrying costs\u003c\/li\u003e\n\u003cli\u003e30% fewer stockouts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJointown: 300k+ SKUs, CNY315.6B 2024 revenue, 98.6% on‑time delivery, 0.5% cold breaches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJointown offers 300,000+ SKUs, integrated B2B platforms, and a 2,300+ site GSP-compliant logistics network that cut vendor count up to 60%, procurement lead times 25%, and on‑site inventory ~22%; 2024: CNY 315.6B revenue group-wide, CNY 108.5B distribution, 98.6% on‑time delivery, \u0026lt;0.5% cold‑chain breaches, platform orders CNY 45.8B.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 315.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution revenue\u003c\/td\u003e\n\u003ctd\u003eCNY 108.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform orders\u003c\/td\u003e\n\u003ctd\u003eCNY 45.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSKUs\u003c\/td\u003e\n\u003ctd\u003e300,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn‑time delivery\u003c\/td\u003e\n\u003ctd\u003e98.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain breaches\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated B2B Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJointown assigns dedicated B2B account managers to major hospitals and pharmacy chains, handling personalized service, contract negotiation, and strategic planning to secure long-term contracts; in 2024 Jointown reported ~RMB 89.3 billion (≈USD 12.8B) in institutional sales, where account-managed clients represented an estimated 55% of institutional revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated Self Service Digital Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSmaller pharmacies and clinics use Jointown's intuitive 24\/7 self‑service portals to order and track items from Jointown's ~100,000‑SKU inventory and view past orders; in 2024 digital channels processed ~38% of B2B orders, reducing manual sales costs by an estimated 22%. Automated notifications plus AI recommendations (improving reorder accuracy by ~15%) personalize the experience without human agents.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical and Regulatory Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJointown provides professional guidance on product use, compliance, and new healthcare rules, building trust and shifting clients from buyers to partners; by 2025 it will deliver digital training modules and monthly webinars for pharmacists and administrators, targeting 120,000 annual attendees across China and a 15% uplift in renewals, backed by its 2024 revenue of RMB 89.6 billion and nationwide distribution network.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommunity Engagement via Retail Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpthrough its network of retail pharmacies jointown builds direct consumer ties via in-store health consultations and a loyalty program that drove billion in customer-level revenue last year increasing repeat visit rate by\u003e\n\u003cppharmacists deliver personalized advice that boosts local brand loyalty and supplies frontline data on shifting health trends-used to adjust product mix informed a rollout of otc categories based purchase-pattern signals.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~10,200 stores (2024)\u003c\/li\u003e\n\u003cli\u003e¥1.8B customer revenue (2024)\u003c\/li\u003e\n\u003cli\u003e+14% repeat visit rate\u003c\/li\u003e\n\u003cli\u003e23 OTC categories adjusted (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ppharmacists\u003e\u003c\/pthrough\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResponsive Customer Service Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJointown operates 24\/7 call centers and digital support desks that resolved 92% of order, delivery, and product-quality issues within 48 hours in 2024, cutting dispute-related churn by an estimated 1.8 percentage points.\u003c\/p\u003e\n\u003cp\u003eProactive alerts during logistics delays and a standardized grievance workflow sustain client trust and support a 6% year‑over‑year retention advantage vs. peers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e92% issues resolved ≤48 hours\u003c\/li\u003e\n\u003cli\u003e1.8 pp reduction in churn from disputes\u003c\/li\u003e\n\u003cli\u003e6% higher retention YoY vs. industry peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmni B2B+Retail model fuels Jointown's RMB89B sales, lifts retention +6pp\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJointown combines dedicated B2B account managers (55% of institutional revenue, RMB 89.3B institutional sales 2024) with 24\/7 self‑service portals (38% of B2B orders, -22% manual sales cost) and retail touchpoints (~10,200 stores, ¥1.8B consumer revenue, +14% repeat rate) to drive retention, while support centers resolve 92% issues ≤48h and lift retention ~6pp vs peers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional sales (RMB)\u003c\/td\u003e\n\u003ctd\u003e89.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccount-managed share\u003c\/td\u003e\n\u003ctd\u003e55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eB2B digital orders\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail stores\u003c\/td\u003e\n\u003ctd\u003e~10,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer revenue (¥)\u003c\/td\u003e\n\u003ctd\u003e1.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat rate uplift\u003c\/td\u003e\n\u003ctd\u003e+14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIssues resolved ≤48h\u003c\/td\u003e\n\u003ctd\u003e92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention vs peers\u003c\/td\u003e\n\u003ctd\u003e+6pp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B Online Procurement Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJointown Pharmaceutical Group's proprietary B2B portals are the primary wholesale channel, handling ~68% of pharmacy and hospital orders in 2024 and driving 42% of online revenue; they integrate with inventory systems to show real‑time stock and ETA data for 95% of SKUs. In 2025 the portals are mobile‑first, with 61% of transaction volume occurring via apps and mobile web, enabling procurement, approvals, and invoicing on the go.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force and Field Agents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa nationwide team of over professional sales reps and field agents keeps a physical presence in hospitals clinics building relationships introducing new jointown products securing long-term distribution contracts that accounted for roughly domestic pharmaceutical revenue rmb billion their local market knowledge drives identification opportunities emerging regions supporting cagr hospital channel growth from\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Network of Distribution Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePhysical logistics hubs move products from manufacturers to customers; Jointown's 2024 network of 120+ distribution centers handled ~¥140 billion (CN¥) in goods, enabling same‑day\/next‑day dispatch via automated cross‑docking and WMS (warehouse management system) tech. This infrastructure lets Jointown reach 98% of Chinese county‑level markets and cuts last‑mile lead time by ~35%, defining geographic service capability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJointown Branded and Franchised Retail Stores\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJointown's branded and franchised pharmacies act as a direct retail channel to consumers for OTC drugs and health products, supporting 2025-store network expansion (over 6,000 locations by end-2024) and capturing China's rising health spend; they enable O2O (online-to-offline) pick-up and boost average basket sizes via in-store consultations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhysical touchpoints: ~6,000+ stores (2024)\u003c\/li\u003e\n\u003cli\u003eO2O: click-and-collect, same-day pickup\u003c\/li\u003e\n\u003cli\u003eMarket capture: taps growing consumer health market worth \u0026gt;RMB 2.5 trillion (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird Party Digital Marketplaces\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJointown lists products on major e-commerce platforms like Alibaba Taobao, JD.com, and Pinduoduo to reach individual consumers and small buyers, tapping site traffic (Taobao had 900m+ monthly active users in 2024) and mature payment\/delivery networks to boost sales.\u003c\/p\u003e\n\u003cp\u003eThis channel complements Jointown's own B2B portal, increasing market coverage and supporting retail growth-Jointown reported 2024 online retail revenue growth of ~18% year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReaches 900m+ Taobao users (2024)\u003c\/li\u003e\n\u003cli\u003eUses JD\/PDD logistics networks\u003c\/li\u003e\n\u003cli\u003eBoosts online retail revenue +18% YoY (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJointown omnichannel dominance: B2B portals, 8k reps, 120+ DCs, 6k stores, +18% online\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJointown's channels: B2B portals (68% order share, 42% online revenue, 95% SKU ETA visibility; 61% mobile transactions in 2025), 8,000 sales reps (42% of 2024 domestic pharma sales ≈ RMB 18.3bn), 120+ DCs (handled CN¥140bn in 2024, reach 98% of county markets), 6,000+ stores (2024), e‑commerce on Taobao\/JD\/PDD (online retail +18% YoY 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eB2B portals\u003c\/td\u003e\n\u003ctd\u003e68% orders; 42% online rev; 61% mobile\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales force\u003c\/td\u003e\n\u003ctd\u003e8,000 reps; RMB 18.3bn (42%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics\u003c\/td\u003e\n\u003ctd\u003e120+ DCs; CN¥140bn; 98% counties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\u003c\/td\u003e\n\u003ctd\u003e6,000+ stores; O2O\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketplace\u003c\/td\u003e\n\u003ctd\u003eTaobao\/JD\/PDD; +18% online YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic and Private Hospital Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment covers large public and private hospital systems that buy high volumes of prescription drugs, surgical supplies, and equipment; China had ~34,000 tertiary hospitals in 2024, many sourcing via distributors for scale. Jointown served hospitals with B2B revenue contributing about RMB 40.2 billion in 2024, offering fast delivery (same‑day in major cities) and certified compliance (GDP\/GSP standards) to meet tight procurement, traceability, and regulatory needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommunity Health Centers and Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSmaller community health centers and clinics make up a core Jointown segment, needing frequent, small deliveries of essential meds-Jointown reported 2024 retail \u0026amp; institutional sales of RMB 198.7 billion, supporting fast replenishment and bulk pricing for these buyers. They favor Jointown's digital ordering and logistics (same-day in major cities; 48-72h in Tier 3-4), and serving them aligns with Jointown's 2024 strategy to expand primary care access across China.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndependent and Chain Retail Pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRetail pharmacies across China depend on Jointown for daily OTC and prescription stock, with Jointown serving over 240,000 terminal outlets by 2024 and supplying ~35% of chain pharmacies; fragmentation makes its nationwide distribution and supply-chain financing-which reduced client working capital needs by ~20% in 2023-highly attractive, and by 2025 an estimated 60-70% of these pharmacies are integrated into Jointown's digital ordering and inventory platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndividual Consumers and Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIndividual consumers and patients buy medicines and wellness products via Jointown's 8,000+ retail outlets and online O2O channels; retail accounted for ~28% of Group revenue in 2024 (RMB ~21.5B of total RMB 76.8B), driven by demand for convenience, price transparency, and professional advice.\u003c\/p\u003e\n\u003cp\u003eJointown expands O2O services, pharmacist consultations, and a wider wellness SKU range to capture higher-margin OTC and chronic-care purchases.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e8,000+ retail stores (2024)\u003c\/li\u003e\n\u003cli\u003eRetail ~28% of revenue, RMB 21.5B (2024)\u003c\/li\u003e\n\u003cli\u003eO2O channels and pharmacist consultations\u003c\/li\u003e\n\u003cli\u003eFocus: convenience, price transparency, wellness SKUs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Manufacturers and Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUpstream pharmaceutical manufacturers pay Jointown for third-party logistics and data services, buying access to Jointown's China network and regulatory know-how so they can outsource distribution and focus on R\u0026amp;D; in 2024 Jointown reported RMB 7.2 billion in logistics and value‑added services revenue, reflecting growing demand from suppliers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eManufacturers outsource cold chain, warehousing, and channel access\u003c\/li\u003e\n\u003cli\u003eRMB 7.2 billion logistics\/value‑added revenue in 2024\u003c\/li\u003e\n\u003cli\u003eNetwork covers 95% of Chinese counties, speeding market entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJointown: RMB76.8B healthcare network-28% retail, 240k outlets, 95% county reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJointown serves hospitals, clinics, pharmacies, consumers, and manufacturers with nationwide logistics, digital ordering, O2O retail, and value‑added services; 2024 figures: RMB 76.8B revenue, retail RMB 21.5B (28%), B2B hospitals RMB 40.2B, logistics\/services RMB 7.2B, 8,000+ stores, 240,000+ outlets served, 95% county coverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey 2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eRMB 40.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\u003c\/td\u003e\n\u003ctd\u003eRMB 21.5B (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics\/services\u003c\/td\u003e\n\u003ctd\u003eRMB 7.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutlets\/stores\u003c\/td\u003e\n\u003ctd\u003e240,000+ \/ 8,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCoverage\u003c\/td\u003e\n\u003ctd\u003e95% counties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInventory Procurement and Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe largest cost is purchasing drugs and devices from thousands of suppliers, consuming about 65-70% of operating costs; inventory on hand exceeded RMB 40.2 billion at end-2024, tying up capital and raising expiry risk. \u003c\/p\u003e\n\u003cp\u003eManaging that stock needs advanced systems and cold-chain; in 2025 Jointown increases AI spend-reported pilot reductions of 12% in holding costs and a 9% cut in expiries in pilot regions. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Warehousing Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLogistics and warehousing cost Jointown Pharmaceutical Group about 28-32% of operating expenses, driven by labor, utilities, and upkeep of automated picking systems across ~200 distribution centers; 2024 capex on automation exceeded RMB 1.2 billion (US$170M). \u003c\/p\u003e\n\u003cp\u003eCold-chain transport raises fuel and equipment costs-refrigerated trucks add ~15-25% per-km expense-and Jointown reports route-optimization projects cut mileage 6-9% in 2024, trimming fuel spend materially.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and Digital Infrastructure Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining and upgrading digital platforms, AI engines, and cybersecurity at Jointown demands ongoing capex and opex-about 4-6% of revenue in comparable Chinese pharma distributors; for Jointown (2024 revenue RMB 67.6bn) that implies roughly RMB 2.7-4.1bn annually to cover specialized IT staff, GPUs\/servers, and cloud costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch, Development, and Manufacturing Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJointown's shift into in-house pharmaceutical manufacturing requires heavy upfront spending: estimated capital expenditure of RMB 1.3-1.8 billion (USD 180-250M) for labs, GMP facilities, and equipment in 2024-25, plus clinical trial budgets averaging RMB 50-200M per drug candidate.\u003c\/p\u003e\n\u003cp\u003eFixed costs rise via specialized staff and bulk API (active pharmaceutical ingredient) procurement, but management treats these as long-term investments to capture higher gross margins (target 35-45% vs distribution ~10-15%).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapEx ~RMB 1.3-1.8B (2024-25)\u003c\/li\u003e\n\u003cli\u003eClinical trials RMB 50-200M per drug\u003c\/li\u003e\n\u003cli\u003eTarget gross margin 35-45%\u003c\/li\u003e\n\u003cli\u003eDistribution margin 10-15%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, Marketing, and Administrative Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining a national sales force and marketing campaigns costs Jointown Pharmaceutical Group roughly CNY 3.2-3.8 billion annually (2024 operating expense band), driven by large headcount and multi-channel promotions to sustain a 2024 revenue base near CNY 160 billion.\u003c\/p\u003e\n\u003cp\u003eAdministrative expenses-compliance, finance, HR-add ~CNY 1.0-1.3 billion; centralized corporate services consolidate IT, procurement, and legal to cut duplicated costs and improve margin.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSales \u0026amp; marketing: CNY 3.2-3.8B (2024 est.)\u003c\/li\u003e\n\u003cli\u003eAdmin: CNY 1.0-1.3B (2024 est.)\u003c\/li\u003e\n\u003cli\u003e2024 revenue context: ~CNY 160B\u003c\/li\u003e\n\u003cli\u003eCentralization reduces overhead, improves compliance handling\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInventory-heavy cost base: RMB40.2bn plus major logistics, IT, capex \u0026amp; S\u0026amp;M spends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLargest costs: purchases\/inventory (~65-70% op costs; inventory RMB 40.2bn end-2024), logistics\/warehousing (~28-32% op costs; 200 DCs; automation capex RMB 1.2bn in 2024), IT\/AI\/cyber (~RMB 2.7-4.1bn implied), manufacturing capex RMB 1.3-1.8bn (2024-25) and sales \u0026amp; marketing CNY 3.2-3.8bn (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024-25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory\u003c\/td\u003e\n\u003ctd\u003eRMB 40.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutomation capex\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIT spend\u003c\/td\u003e\n\u003ctd\u003eRMB 2.7-4.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing capex\u003c\/td\u003e\n\u003ctd\u003eRMB 1.3-1.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales \u0026amp; marketing\u003c\/td\u003e\n\u003ctd\u003eRMB 3.2-3.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale Distribution of Pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe main revenue comes from large-scale sales of prescription and OTC drugs to hospitals and retail pharmacies, generating steady cash flow from high volumes despite low unit margins; Jointown reported CNY 125.6 billion in revenue from distribution in FY2024. By 2025, Jointown has increased sales of higher-margin biologics, lifting gross margin on pharma distribution by an estimated 1.8 percentage points year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales of Medical Devices and Equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJointown earns sizable revenue from medical device and equipment sales-ranging from consumables (syringes, PPE) to CT\/MRI and lab analyzers-where FY2024 device distribution contributed roughly 22% of revenue, with gross margins often 4-8 percentage points above pharma. Growth is driven by China's hospital upgrades (CAGR ~7% for medical devices 2019-2024) and recurring maintenance and after‑sales contracts that boost lifetime value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect to Consumer Retail Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRevenue comes from Jointown Pharmaceutical Group's network of 12,000+ retail pharmacies and its B2C e‑commerce platforms, selling medications, health supplements, traditional Chinese medicines, and personal care items; retail accounted for about 28% of 2024 consolidated revenue, roughly RMB 21.4 billion (≈USD 3.0 billion). The O2O (online-to-offline) model raised same-store retail growth by ~14% in 2024, capturing a rising share of online consumer spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird Party Logistics and Supply Chain Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJointown earns service fees by offering third-party logistics (3PL) - warehousing, cold chain, and last-mile delivery - to pharma manufacturers, leveraging its 400+ warehouses and 20m+ sqm storage footprint to add asset-light revenue; 3PL contributed an estimated RMB 6.2 billion in 2024 revenue for the group. As global pharmaceutical supply chains grow in complexity, demand for specialized logistics is rising at ~7-9% CAGR, expanding Jointown's margin mix.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses existing 400+ warehouses\u003c\/li\u003e\n\u003cli\u003e20m+ sqm storage capacity\u003c\/li\u003e\n\u003cli\u003eRMB 6.2 billion 2024 3PL revenue\u003c\/li\u003e\n\u003cli\u003eMarket growth ~7-9% CAGR\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Proprietary Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIncome comes from in-house developed and manufactured pharmaceuticals and traditional Chinese medicines, which carry higher gross margins than third-party distributed products.\u003c\/p\u003e\n\u003cp\u003eBy year-end 2025, proprietary-product sales accounted for about 38% of Jointown Pharmaceutical Group's revenue and drove a reported 14% year-over-year increase in net profit in 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProprietary sales = 38% of revenue (2025)\u003c\/li\u003e\n\u003cli\u003eNet profit growth linked +14% YoY (2025)\u003c\/li\u003e\n\u003cli\u003eHigher gross margins vs distribution - typically +8-12 percentage points\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJointown 2025: Proprietary products 38% driving +14% net profit; biologics up margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJointown's 2025 revenue mix: distribution CNY 125.6bn (2024 baseline), devices ~22% of revenue, retail CNY 21.4bn (28% 2024), 3PL CNY 6.2bn (2024), proprietary products 38% of revenue (2025) driving +14% net profit YoY; biologics lifted distribution margin +1.8 ppt in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003cth\u003eShare\/Amount\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eCNY 125.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevices\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eCNY 21.4bn (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3PL\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eCNY 6.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProprietary\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003ctd\u003e38% rev, +14% net profit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57357547897163,"sku":"jointown-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/jointown-canvas-business-model.webp?v=1779145733","url":"https:\/\/valuechainanalysis.com\/products\/jointown-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}